Witzig Thomas E
Department of Hematology/Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Semin Oncol. 2003 Dec;30(6 Suppl 17):11-6. doi: 10.1053/j.seminoncol.2003.10.007.
Radioimmunotherapy, an emerging treatment option for certain patients with non-Hodgkin's lymphoma (NHL), enables the targeting of cytotoxic radiation to tumor cells with minimal irradiation of normal cells. Yttrium 90 ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA) was approved in February 2002 for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell NHL, including patients with rituximab-refractory NHL. Yttrium 90 ibritumomab tiuxetan is an effective treatment with a consistent overall response rate of 73% to 83%. It has a good safety profile and is generally well tolerated in the indicated population. The results of clinical trials show that (90)Y ibritumomab tiuxetan can be used effectively and safely in many patients with NHL, including those with mild thrombocytopenia and those with disease that is refractory to rituximab, without the adverse events associated with conventional chemotherapy and external beam radiation therapy. The use of (90)Y ibritumomab tiuxetan does not preclude subsequent therapy with other conventional treatment options.
放射免疫疗法是某些非霍奇金淋巴瘤（NHL）患者的一种新兴治疗选择，它能将细胞毒性辐射靶向肿瘤细胞，同时使正常细胞受到的辐射最小化。钇90替伊莫单抗（泽瓦林；百健艾迪公司，马萨诸塞州剑桥）于2002年2月被批准用于治疗复发或难治性低度、滤泡性或转化型B细胞NHL患者，包括对利妥昔单抗难治的NHL患者。钇90替伊莫单抗是一种有效的治疗方法，总体缓解率持续在73%至83%。它具有良好的安全性，在指定人群中一般耐受性良好。临床试验结果表明，钇90替伊莫单抗可有效且安全地用于许多NHL患者，包括轻度血小板减少症患者和对利妥昔单抗难治的疾病患者，且不会出现与传统化疗和外照射放疗相关的不良事件。使用钇90替伊莫单抗并不排除后续采用其他传统治疗方案。
